[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519942":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Hubei Cancer Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"OFS continues to use after 5 years",null,"HR-positive premenopausal female patients whose doctors believe that they can benefit from continued use of OFS after 5 years should be included in the trial group.",[13,14],"Drug: OFS continues to use group after 5 years use","Diagnostic Test: Immunohistochemical detection of HR status",{"label":16,"type":10,"description":17,"interventionNames":10},"OFS discontinues to use after 5 years","The control group did not need to continue to use OFS, either leuprolide or goserelin",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","OFS continues to use group after 5 years use","Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.",[9],[25],"OFS discontinues to use group after 5 years use",{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"DIAGNOSTIC_TEST","Immunohistochemical detection of HR status","Enrolled patients must be HR-positive premenopausal breast cancer patients",[9],[32],{"name":33,"affiliation":34,"role":35},"Hongmei Zheng, Doctor","Study Principal Investigator","PRINCIPAL_INVESTIGATOR",[37,42],{"name":33,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","18971624606","+86","zhenghongmeicj@163.com",{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},"Xinhong Wu, Doctor","18602726300","wuxinhong_9@sina.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":10,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Wu Xinhong","RECRUITING","Wuhan","Hubei","China","CN",{"type":55,"coordinates":56},"Point",[57,58],114.26667,30.58333,{"lat":58,"lon":57},[61],{"name":62,"role":38,"phone":63,"phoneExt":10,"email":45},"xinhong wu, Dr","+8618602726300",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Hongmei Zheng, PhD","vice director","100519942","the-benefits-of-continued-use-of-ovarian-function-suppression-after-5-years-100519942",false,"NCT06050109","The Benefits of Continued Use of Ovarian Function Suppression After 5 Years","A Multicenter, Open-label, Non-randomized Controlled Real World Study Comparing the Benefits of Continued Use of Ovarian Function Suppression After 5 Years","Inclusion Criteria:\n\n* Diagnosed with early primary breast cancer\n* Female aged 18-60 years (including 18 year and 60 year)\n* Hormone receptor (HR) positive HER2 negative\n* Receive 5 years of OFS treatment\n* ECOG score 0-1\n* Voluntarily join this study and sign the informed consent form;\n* The researcher believes that it can benefit.\n\nExclusion Criteria:\n\n* The patient is receiving treatment that affects OFS at the same time The patient has received OFS treatment for less than 5 years\n* Central nervous system metastases with known obvious symptoms, such as headache, cerebral edema, blurred vision\n* Invasive metastases with known obvious symptoms\n* Invasive metastases with known obvious symptoms\n* Doctors think it is not suitable for inclusion","FEMALE","18 Years","60 Years",{"count":79,"type":80},1200,"ESTIMATED","OBSERVATIONAL","To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS.\n\nThis study is a multicenter, prospective, observational, non randomized controlled, open-label real world study based on hospital medical record system data, aimed at evaluating the benefits of continuing to use OFS after 5 years of use. The retrospective analysis plan includes patient data from September 1, 2023 to September 1, 2026. Join two cohorts: the continued use group and the discontinued use group after 5 years of OFS, respectively.",[84,85],"Breast Cancer Female","Endocrine Therapy",[87,88,89,90,91],"ovarian function suppression","Hormone receptor (HR) positive","HER2 negative","early breast cancer","prolonged therapy","2025-03-14",{"date":94,"type":95},"2025-03-17","ACTUAL",{"date":97,"type":95},"2023-09-01",{"date":99,"type":80},"2028-09-01",{"name":66,"class":6},1]